Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Getinge introduces DPTE-BetaBag® with material from renewable sources

Getinge demonstrates its commitment to sustainable innovations by launching a new version of the DPTE-BetaBag®, used in sterile transfer. A new beta section made with the majority of plastic from renewable sources reduces the carbon footprint of the bag without compromising its sterile transfer capabilities. “More and more customers are demanding environmental action and we are up for the challenge,” says Anis Kara, Product Line Manager Life Science at Getinge. Introduced 60 years ago, DPTE® was the world’s first mechanical containment system. The completely leak tight system

Shoan Etemadi appointed new Managing Director of Hemköpskedjan

Hemköpskedjan’s current Deputy Managing Director and Head of Sales, Shoan Etemadi, has been recruited to the role as Managing Director of Hemköpskedjan, and will as of 15 August 2024 succeed Simone Margulies in conjunction with her assuming the role as President and CEO of Axfood.From 15 August, Shoan Etemadi will succeed Simone Margulies as Managing Director of Hemköpskedjan AB. He will also become a member of the Executive Committee of Axfood AB. Currently, Shoan is Deputy Managing Director of Hemköpskedjan, in which Hemköp and Tempo is included, and also Head of Sales since three years.

Study on Patients' Willingness to Pay Published in an International Scientific Journal

AcuCort AB has announced that an article on a study regarding Swedish patients' willingness to pay for Zeqmelit® will be published in the scientific journal Journal of Health Economics and Outcomes Research.The scientific study presented in the article is titled Treatment preferences for acute allergic reactions – a discrete choice experiment in Sweden. The study investigates the willingness to pay for a corticosteroid oral film among Swedish individuals with acute allergic reactions. The premise is that corticosteroids are a common treatment for acute allergic reactions, and the oral film

STILFOLD and PaperShell: Hacking wood and steel with origami

STILFOLD and PaperShell will use the Origami Code to Maximize Material Efficiency in several Manufacturing Industries. The partners will embody this ambition in a joint exhibition this summer, encouraging the industry to join their DESIGN EXHIBITION for innovation and sustainability.STILFOLD, the origami-based design and technology company, is proud to announce a strategic partnership with PaperShell, pioneers in sustainable paper-based composite materials. This alliance is not only a significant step forward for both companies but also a call to colleagues in design, architecture,

CLS focuses on the Neurosurgery business area to optimize capital allocation, secure profitability targets and implement associated cost savings

Lund, Sverige – Clinical Laserthermia Systems AB (publ) (”CLS” or ”the Company”) today announces that the Company has decided to revise its strategy to increase the possibility to achieve the Company's prioritized goal of reaching a positive cash flow in 2026. The revised strategy means the Company prioritizes and increases its investment in the neurosurgery business area, which is expected to result in significantly improved profitability during the period 2024-2026. The focus on neurosurgery also enables significant cost savings for the Company of approximately SEK 65 million during the

Citycon Oyj resolved on a directed share issue without payment for reward share payment

CITYCON OYJ   Stock Exchange Release 21 May 2024 at 9:45Based on the share issue authorisation granted by the Annual General Meeting held on 19 March 2024, the Board of Directors of Citycon Oyj resolved on an issue of 190 000 new shares without consideration to the former CEO for payment of reward shares in accordance with the terms and conditions of the CEO Restricted Share Plan 2021-2025. The shares will be transferred as a reward from the vesting period 2021-2025. The plan ends after the payment of the reward.There is an especially weighty financial reason for deviating from the

AEGIRBIO AB SUCCESSFULLY COMPLETES AN ADDITIONAL MILESTONE OF RADx® TECH PROGRAM

Leading Diagnostics Innovator Advances Accessibility Project for Multiplex TestingAegirBio AB, a forefront leader in saliva-based diagnostics solutions, proudly announces the successful completion of an additional Milestone  in its participation in the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program. AegirBio's phase 1 award, focusing on an accessibility project for multiplex testing, positions the company at the forefront of digital self-test platform development with potential milestone-based payments of up to USD 1.2 million. The RADx® Tech

Stayble Therapeutics publishes interim report for the first quarter of 2024

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its interim report for the first quarter of 2024. The report is available as an attached document and on the Company’s website, https://staybletherapeutics.com/investor-relations/financial-reports/. Below is a summary of the report.Summary   Highlights during the first quarter (January – March 2024) · In January, the final data analysis of the phase IIb study with STA363 against degenerative disc disease was announced. Consistent with the preliminary topline analysis communicated in November 2023, the subgroup

Wetteri Plc interim report for 1 January to 31 March 2024: Favourable first quarter – strong growth in revenue

Wetteri Plc Interim report 21 May 2024 at 9.30 EETSummary of the review period 1 January to 31 March 2024     · The Group’s revenue was EUR 144.8 million (EUR 87.8 million), 65% growth   · Adjusted EBITDA was EUR 6.1 million (EUR 5.4 million)   · The adjusted operating profit was EUR 2.5 million (EUR 2.6 million)   · The operating profit was EUR 1.1 million (EUR 0.7 million)   · The revenue of the Passenger Cars segment increased by EUR 47.3 million (93%) year-on-year  · The revenue of the Maintenance Services segment increased by EUR 11.0 million (76%) year-on-year

Transcom Holding AB (publ) announces changes in the Board of Directors

Transcom Holding AB today announced changes to their Board of Directors following the AGM on May 15. Julius Höh was elected Director of the Board, replacing Herman Korsgaard, who steps down from the board to focus on other duties within Altor. The changes are effective as of May 15, 2024. “I’d like to welcome Julius Höh to the Board. His background in truly international companies in combination with a specialization in the service industry will be very valuable. I’d like to thank Herman Korsgaard for his contributions during his time on the Board”, says Fredrik Cappelen, Chairman of the

Shape Robotics - Interim report Q1 2024

Company Announcement no. 22-24Copenhagen, May 21, 2024 This announcement is a summary and should be read in conjunction with Shape Robotics’ interim report for January – March 2024 (Q1 interim report), published on 21 May 2024. The interim report will be available on the company’s website. Financial highlights The results from the first 3 months of 2024 · Net sales and operating result Net salesQ1 2024 was TDKK 34.871 (18.980). Adjusted EBITDA was -6.960 (-1.395) and EBITDA TDKK -7.453 (-1.395) · Balance sheet and equity ratio Total assets amounted to TDKK 283.313

Crunchfish publishes interim report Q1 2024

Today, Crunchfish AB (“Crunchfish”) publishes the company’s interim report for the first quarter of 2024. Below is a brief summary of the report.+----------------------------------+----------+----------+-----------+|Group Financials |2024-01-01|2023-01-01|2023-01-01 || |2024-03-31|2023-03-31|2023-12-31 |+----------------------------------+----------+----------+-----------+|Net sales (SEK) |1 665 338 |170 572 |987 834 |+----------------------------------+----------+----------+-----------+|Profit or loss

Negative Growth Among Consulting Firms in the First Quarter

Consulting firms in the Nordics faced challenges in Q1, with the majority showing negative growth figures. The average growth rate fell to -1.2 percent compared to 15.1 percent a year ago. However, profit margins remained relatively high, and only one out of 24 companies posted a loss. This is shown in Cinode's latest summary of the Q1 reports of listed consulting firms in the Nordics ."We are seeing continued weak demand across large parts of the market, especially in IT projects. At the same time, many consulting firms have reduced

BioStock: Iconovo initiates development of inhaled obesity treatment

Iconovo has filed a broad patent application for inhaled GLP-1 receptor agonists, used for the treatment of obesity and type 2 diabetes. This is a rapidly growing market, and Iconovo aims to introduce a more patient-friendly alternative to today’s injections.– This marks the first step in Iconovo’s new initiative to develop more convenient, reliable, and cost-effective treatments for obesity, the company stated.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/iconovo-initiates-development-of-inhaled-obesity-treatment/ This is a

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS21 May 2024 at 09:15NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Holding Investment Förvaltning i Luleå ABPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Johan LarssonPosition: Chief Executive Officer(2):Person Discharging Managerial Responsibilities In IssuerName: Mikael RitolaPosition: Other senior managerIssuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS21 May 2024 at 09:15NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: BINGAB Barents Investment Group ABPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Johan LarssonPosition: Chief Executive OfficerIssuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 63439/5/6 ____________________________________________Transaction date: 2024-05-17

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS21 May 2024 at 09:15NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Johan LarssonPosition: Chief Executive Officer Issuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 63436/5/4 ____________________________________________Transaction date: 2024-05-17Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)Instrument type: SHAREISIN: FI4000153515Nature of transaction: ACQUISITION  Transaction details(1): Volume:

Katalysen Ventures publishes report for the First Quarter 2024

Katalysen Ventures AB (publ) hereby publishes the report for the First Quarter 2024. The full report is available immediately as an attached document, and on the company's website. Below is a summary of the report.KPIs: · Number of ventures in portfolio at end of period: 26 (25) · Estimated portfolio market value at end of period: 160 MSEK (149 MSEK) · Cash resources in bank at end of period: 1.2 MSEK (1.3 MSEK) General Financial KPIs: Key Figures (Group*, TSEK) Q1 2024 Q1 2023 2023-01-01 2023-12-31Net

Interim report January – March 2024

First quarter in brief · Net sales amounted to 17.8 million SEK (16.1), which means a sales growth of 10 percent.  · Operating profit amounted to 2.7 million SEK (-2), corresponding to an operating margin of 15 percent (-13).  · Net profit for the period amounted to 3.4 million SEK (-2,2).  · Earnings per share amounted to 0.08 SEK (-0.05). Significant events during the first quarter In February 2024, the extraordinary general meeting decided to establish a long-term incentive program. SyntheticMR has received FDA 510K approval for SyMRI 3D. Significant events

Valio's leading project, Food 2.0, is progressing – presenting the key personnel and research themes

In February, Valio announced that it has been selected by Business Finland as a leading company to start the Food 2.0 project, which is an ongoing effort to develop the food system of the future and promote the competitiveness of food exports. Veera Virtanen has been appointed Ecosystem Lead of the partner ecosystem within the project. Around 50 business and community partners have already joined the ecosystem, and the goal is at least one hundred partners.“For food production, a genuine circular economy means that nutrients, energy and side streams circulate: everything produced along the

AstraZeneca to deliver $80bn revenue by 2030

21 May 2024 AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and  sustained growth post 2030 Launch of 20 new medicines expected by 2030 Significant growth from existing oncology, biopharmaceuticalsand rare disease portfolios Investing in disruptive innovation that will shape the future of medicine anddrive long-term growth Decoupling carbon emissions from revenue growth   Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth

Fayes Investeringar 1 AB completes the recommended cash offer to the shareholders of Awardit AB (publ) and thereby becomes the owner of 61.5 per cent of the shares, and extends the acceptance period

The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of shareholders in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States of America (the “US”), or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law or

Beyond Frames Entertainment AB (publ) Appoints Emma Partin as New Chief Financial Officer

Stockholm, May 21, 2024 - Beyond Frames Entertainment AB (publ), a leader in immersive gaming and interactive entertainment, is pleased to announce the appointment of Emma Partin as the new Chief Financial Officer, effective immediately. Emma Partin brings with her 15 years of extensive experience in management consulting from Deloitte, where she has been instrumental in guiding international companies through Finance strategies and transformation programs, IPOs preparations, mergers and acquisitions, and post-merger integration.Emma's proven track record in driving financial excellence and

There are no items matching the current filter
There are no more items matching the current filter
Back to top